RAC 2.30% $1.49 race oncology ltd

[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-83

  1. 1,630 Posts.
    lightbulb Created with Sketch. 631
    Market seems to be loving all the FDA attention you have. Our CEO has shareholder intrests at heart and historical behaviour backing it up. It doesn't need to be a contest but at least the man stirring your hornets nest has science explaining his reasons, don't have to agree with it but at least its stimulating conversations.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.